Weekly Reflection

This week, we have learnt the therapeutic classification of biotechnology products; currently marketed rDNA products and their indications; currently marketed MAb products and their indications; and principles associated with handling, storage and administration of biotechnology products.

Here are some key points for you to review what you have learnt this week. There is no need to answer them all. You could use these to check the gist of this week.

1. Stay current with new biologics approval by consulting with this [web links] (https://www.accessdata.fda.gov/scripts/CDER/daf/index.cfm?event=report.page)

2. To be able to name at least one product for each of the following therapeutic classes of biologics: Anticoagulant/Coagulant, Antisense, Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Interferons, Interleukins, Reverse Transcriptase Inhibitors, Tissue Necrosis Factors and Tyrosine Kinase Inhibitors

3. To be ready for opportunities to play multiple roles as a consultant to the physician, as an advisor to the patient and as an advocate for the under-served. Of particular importance is to assist with product selection, genetic screening for efficacy/safety, and product accessibility and pricing (particularly in the case of Biosimilars).